128 related articles for article (PubMed ID: 12235519)
41. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost.
Boeve S; Strupeck J; Creech S; Stiff PJ
Bone Marrow Transplant; 2004 May; 33(10):997-1003. PubMed ID: 15064690
[TBL] [Abstract][Full Text] [Related]
42. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
[TBL] [Abstract][Full Text] [Related]
43. Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses.
Suh C; Kim HJ; Kim SH; Kim S; Lee SJ; Lee YS; Kim EK; Kim SB; Lee JS; Kim MW; Kim K; Yoon SS
Transfusion; 2004 Apr; 44(4):533-8. PubMed ID: 15043569
[TBL] [Abstract][Full Text] [Related]
44. Analysis of parameters affecting engraftment in children undergoing autologous peripheral blood stem cell transplants.
Figuerres E; Haut PR; Olzewski M; Kletzel M
Bone Marrow Transplant; 2000 Mar; 25(6):583-8. PubMed ID: 10734291
[TBL] [Abstract][Full Text] [Related]
45. Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage.
Oza A; Hallemeier C; Goodnough L; Khoury H; Shenoy S; Devine S; Augustin K; Vij R; Trinkaus K; Dipersio JF; Adkins D
Transfusion; 2006 Jan; 46(1):14-23. PubMed ID: 16398726
[TBL] [Abstract][Full Text] [Related]
46. Starting granulocyte-colony-stimulating factor (filgrastim) early after autologous peripheral blood progenitor cell transplantation leads to faster engraftment without increased resource utilization.
Thompson JM; Carlton P; Akard LP; Dugan MJ; Jansen J
Transfusion; 2009 Mar; 49(3):548-54. PubMed ID: 19040494
[TBL] [Abstract][Full Text] [Related]
47. Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis.
Oyama Y; Cohen B; Traynor A; Brush M; Rodriguez J; Burt RK
Bone Marrow Transplant; 2002 Jan; 29(1):81-5. PubMed ID: 11840150
[TBL] [Abstract][Full Text] [Related]
48. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
49. Clinical outcomes and graft characteristics in pediatric matched sibling donor transplants using granulocyte colony-stimulating factor-primed bone marrow and steady-state bone marrow.
Chiang KY; Haight A; Horan J; Olson E; Gartner A; Hartman D; Youssef S; Worthington-White D
Pediatr Transplant; 2007 May; 11(3):279-85. PubMed ID: 17430483
[TBL] [Abstract][Full Text] [Related]
50. A randomised study of 10 microg/kg/day (single dose) vs 2 x 5 microg/kg/day (split dose) G-CSF as stem cell mobilisation regimen in high-risk breast cancer patients.
Carrión R; Serrano D; Gómez-Pineda A; Díez-Martín JL
Bone Marrow Transplant; 2003 Sep; 32(6):563-7. PubMed ID: 12953127
[TBL] [Abstract][Full Text] [Related]
51. CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin.
Dong L; Wu T; Zhang MJ; Gao ZY; Lu DP
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1515-24. PubMed ID: 18022582
[TBL] [Abstract][Full Text] [Related]
52. High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation.
Atta EH; de Azevedo AM; Maiolino A; Coelho CJ; Sarcinelli SM; de Alvarenga Máximo C; Marra VL
Am J Hematol; 2009 Jan; 84(1):21-8. PubMed ID: 19006229
[TBL] [Abstract][Full Text] [Related]
53. Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers.
Goterris R; Hernández-Boluda JC; Teruel A; Gómez C; Lis MJ; Terol MJ; Tormo M; Solano C; Arbona C
Bone Marrow Transplant; 2005 Nov; 36(10):847-53. PubMed ID: 16113660
[TBL] [Abstract][Full Text] [Related]
54. Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow.
Elfenbein GJ; Sackstein R
Exp Hematol; 2004 Apr; 32(4):327-39. PubMed ID: 15050742
[TBL] [Abstract][Full Text] [Related]
55. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
[TBL] [Abstract][Full Text] [Related]
56. Transient respiratory disturbance by granulocyte-colony-stimulating factor administration in healthy donors of allogeneic peripheral blood progenitor cell transplantation.
Yoshida I; Matsuo K; Teshima T; Hashimoto D; Tanimoto Y; Harada M; Tanimoto M
Transfusion; 2006 Feb; 46(2):186-92. PubMed ID: 16441593
[TBL] [Abstract][Full Text] [Related]
57. G-CSF-mobilized haploidentical peripheral blood stem cell transplantation in children with poor prognostic nonmalignant disorders.
Arpaci F; Tezcan I; Kuzhan O; Yalman N; Uckan D; Kürekci AE; Ikincioğullari A; Ozet A; Tanyeli A
Am J Hematol; 2008 Feb; 83(2):133-6. PubMed ID: 17722073
[TBL] [Abstract][Full Text] [Related]
58. Endothelial-like vascular progenitor cells (VPCs) from allogeneic and autologous donors: mobilization features distinct from hematopoietic progenitors.
Allan DS; Dubé P; Roy J; Busque L; Roy DC
Biol Blood Marrow Transplant; 2007 Apr; 13(4):433-9. PubMed ID: 17382249
[TBL] [Abstract][Full Text] [Related]
59. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial.
Valteau-Couanet D; Faucher C; Aupérin A; Michon J; Milpied N; Boiron JM; Bourhis JH; Gisselbrecht C; Vernant JP; Pinna A; Bendahmane B; Delabarre F; Benhamou E
Bone Marrow Transplant; 2005 Sep; 36(6):547-52. PubMed ID: 16007101
[TBL] [Abstract][Full Text] [Related]
60. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors.
Yamasaki S; Henzan H; Ohno Y; Yamanaka T; Iino T; Itou Y; Kuroiwa M; Maeda M; Kawano N; Kinukawa N; Miyamoto T; Nagafuji K; Shimoda K; Inaba S; Hayashi S; Taniguchi S; Shibuya T; Gondo H; Otsuka T; Harada M;
Bone Marrow Transplant; 2003 Sep; 32(5):505-10. PubMed ID: 12942097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
